Last edition
News about "Relapsed/Refractory Cancer Treatment"
GSK plc Secures China Approval for Blenrep Combination Therapy in Multiple Myelom
National Medical Products Administration approves Blenrep with bortezomib and dexamethasone for relapsed or refractory patients, backed by strong phase III trial outcomes.
Relapsed/Refractory Cancer Treatment | 21/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members